乳果糖口服溶液在改善原发性肝癌患者动脉化疗栓塞术后大便困难及腹胀中的临床应用

目的探讨乳果糖口服溶液（LOS）在改善原发性肝癌（HCC）患者TACE术后大便困难及腹胀中的临床应用价值。方法将284例经导管肝动脉化疗栓塞（TACE）治疗的HCC患者随机分组：观察组（142例）术后给予LOS15ml，每日两次，对照组（142例）不服用LOS，当对照组患者出现腹胀、大便困难或便秘时结束观察，给予LOS或增加胃肠动力等对症治疗，观察两组患者术后首次大便时间及腹胀的发生率。结果对照组与观察组术后首次大便时间分别为46．67±12．41h和27．71±7．92h；两组腹胀发生率分别为51．4％比22．5％，差异均有统计学意义（P〈O．05）。观察组4例患者口服LOS后出现胃肠功能亢进，2例脐周隐痛不适，1例出现轻度腹泻，及时停药后好转，均无严重并发症发生。结论乳果糖口服溶液能够一定程度的改善HCC患者TACE术后大便困难，降低腹胀的发生率，在减轻患者不适、加快患者康复方面起着一定得作用，值得临床上推广应用。

Application of lactulose oral solution on alleviating dyschesia and abdominal symptoms after transcatheter arterialchemoembolization of hepatic carcinoma

Objective To investigate the effect of lactulose oral solution （LOS） on patients with dyschesia and bloating post- transcatheter arterial chemoembolization （TACE） of hepatocellular carcinoma （HCC）. Methods Of 284 patients who underwent TACE therapy of HCC, 142 in the observation group were given LOS （15 mL bid ） immediately post-TACE. The remaining 142 patients in the control group were also given LOS when abdominal distension or dyschesia developed. The time of first bowel movement and the incidence of abdominal distension were compared between the two groups. Results The time of first bowel movement was significantly （P 〈 0.05） shorter （27.71 ± 7.92 h） and the incidence of abdominal distension （2.5%） significantly （P 〈 0.05） lower in the observation group than those of the control group （46.67 ± 12.41 h and 51.4%）. Gastrointestinal hyperfunction, umbilical pain and mild diarrhea appeared in 4, 2 and 1 patients, respectively after administration of LOS. The side effects improved after cessation of LOS. Conclusions Lactulose oral solution can reduce dyschesia and incidence of abdominal distension in patients with HCC post-TACE, thus accelerating patient rehabilitation.